5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

The Polycomb group protein EZH2 directly controls DNA methylation

Emmanuelle Viré, Carmen Brenner, Rachel Deplus et al. · Nature · 2005 · 2.2K citations

Chromatin, Epigenetic Change, Genetics +7

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2002 · 1.8K citations

Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder

Ryan M. O’Connell, Dinesh S. Rao, Aadel A. Chaudhuri et al. · The Journal of Experimental Medicine · 2008 · 678 citations · Full text

Immunology, Pathology, Sustained Expression +23

Multilineage Transcriptional Priming and Determination of Alternate Hematopoietic Cell Fates

Peter Laslo, Chauncey J. Spooner, Aryeh Warmflash et al. · Cell · 2006 · 633 citations · Full text

Multilineage Transcriptional Priming, Transcriptional Regulation, Genetics +7